Kogelnik H D
Cancer Clin Trials. 1980 Summer;3(2):179-86.
In April 1976 clinical experience with misonidazole began at the University Clinic for Radiotherapy and Radiobiology of Vienna. Initially the drug was given mainly in four to six divided large doses ranging from 50 to 80 mg/kg (2.1-3.1 g/m2). Since October 1977 daily low doses in the range of 1-2g (0.45-1.3 g/m2) were used. So far over 100 patients with advanced tumor stages have been under investigation. Serum levels for the different treatment schedules are reviewed and sensitizer enhancement ratios larger than 1.3 may be expected even with daily low doses of misonidazole. Neurological side effects are analyzed and related to the cumulative dose (in g/m2) and overall treatment time. Depending on the overall time of drug administration the total dose of misonidazole can be adjusted to avoid undersirable side effects. It is our impression that normal tissue reactions are unchanged by the use of misonidazole. Preliminary results of a randomized clinical trial in patients with high-grade astrocytomas appear to be favorable for the sensitizer group. Als some impressive clinical results were seen in patients when using daily low doses of misonidazole.
1976年4月，维也纳大学放射治疗与放射生物学诊所开始了米索硝唑的临床应用。最初，该药物主要以四至六次大剂量给药，剂量范围为50至80毫克/千克（2.1 - 3.1克/平方米）。自1977年10月起，开始使用每日低剂量，范围为1 - 2克（0.45 - 1.3克/平方米）。到目前为止，已有100多名晚期肿瘤患者接受了研究。对不同治疗方案的血清水平进行了回顾，即使使用每日低剂量的米索硝唑，也有望获得大于1.3的增敏剂增强率。对神经副作用进行了分析，并将其与累积剂量（克/平方米）和总治疗时间相关联。根据药物给药的总时间，可以调整米索硝唑的总剂量以避免不良副作用。我们的印象是，使用米索硝唑后正常组织反应未发生变化。一项针对高级别星形细胞瘤患者的随机临床试验的初步结果似乎对增敏剂组有利。在使用每日低剂量米索硝唑的患者中也观察到了一些令人印象深刻的临床结果。
